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HPV encoded proteins can elicit ectopic protein–protein interactions that re-wire signaling pathways, in a mode
that promotes malignancy. Moreover, accumulating data related to HPV is now providing compelling substantiation
of a central role played by HPV in escaping immunosurveillance and impairment of apoptotic response. What
emerges is an intricate network of Wnt, TGF, Notch signaling cascades that forms higher-order ligand–receptor
complexes routing downstream signaling in HPV infected cells. These HPV infected cells are regulated both
extracellularly by ligand receptor axis and intracellularly by HPV encoded proteins and impair TRAIL mediated
apoptosis. We divide this review into different sections addressing how linear signaling pathways integrate to
facilitate carcinogenesis and compounds that directly or indirectly reverse these aberrant interactions offer new
possibilities for therapy in cancer. Although HPV encoded proteins mediated misrepresentation of pathways is
difficult to target, improved drug-discovery platforms and new technologies have facilitated the discovery of agents
that can target dysregulated pathways in HPV infected cervical cancer cells, thus setting the stage for preclinical
models and clinical trials.Introduction
There is an overwhelming list of research work that un-
derlines the fact that HPV encoded proteins control cell
cycle progression, apoptosis and cell differentiation, and
have emerged as fundamental regulators of cervical can-
cer. Recent studies have revealed a complex network of
protein interactions in HPV infected cells, and have
connected HPV encoded proteins with other key signal-
ing pathways. Such crosstalk has uncovered novel roles
for signalings, including regulation of TGFβ/SMAD,
WNT/β-catenin and Notch signaling cascades by HPV
encoded proteins during carcinogenesis. This review
highlights recent findings and trends in the HPV in-
fected cervical cancer with an emphasis on how the
HPV encoded proteins integrate with other pathways to
promote cervical cancer. Moreover, several clues related
to role of TRAIL mediated signaling in HPV infected
cervical cancer cells are discussed. It also provides a bet-
ter understanding of role of miRNAs in HPV infected
cervical cancer cells. We also review recent patterns and
approaches which have been used to induce apoptosis in* Correspondence: ammadahmad638@yahoo.com
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reproduction in any medium, provided the orHPV infected cervical cancer cells. Oncogenic proteins,
such as those encoded by HPV, frequently form ectopic
signaling complexes to re-constitute cellular behavior
and exemplify how improved understanding of the HPV
associated mechanisms might be translated into clinical
benefit.
Histological studies provide classification of cervical
cancer. Therefore it can be characterized into different
sub-categories, including squamous cell carcinomas (SCC)
and adenocarcinomas (AdCAs). SCCs develop via well-
defined precursor stages, called cervical intraepithelial
neoplasia (CIN, graded 1–3), however precursor stages for
AdCAs are less well characterized. The precursor lesions
to cervical cancers are known as cervical intraepithelial
neoplasia (CIN) and noatably CIN1 lesions are referred to
as low-grade CIN whereas CIN2 and 3 lesions together
are considered high-grade CIN [1,2].
Epidemiological and experimental studies have provided
considerable verification that persistent infections with
high-risk types of HPV (hrHPVs; HPV16, 18, 31, 33, 45)
are causative agents of cervical cancer [3]. Increasing so-
phisticated information has enhanced our knowledge re-
lated to HPV-16 genome. It is a well established fact that
HPV-16 genome is organized into six early (E1, E2, E4,
E5, E6, and E7) and two late (L1 and L2) open readingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spectively. There is a categorization based on functions of
the proteins as E1 and E2 are necessary for replication of
the viral genome, E6 and E7 are responsible for main-
taining the correct environment for DNA replication in
the host cell by preventing possible cell cycle arrest and
intrinsic p53-dependent apoptosis [4–6].
Accumulating evidence on cellular receptor-binding
and internalization pathways of HPVs is providing fur-
ther insights into the function of the pathways involved,
their constituent proteins and ways in which they gain
entry into host cells. There are wide-ranging pathways
which are documented to be used by HPV including
clathrin-mediated endocytosis, caveolar endocytosis,
clathrin- and caveolae-independent pathway. Details can
be found elsewhere [7,8]. It has previously been specu-
lated that virus enters into host cell simplistically how-
ever it is now evident that HPV interacts with different
molecules extracellularly for rapid activation of signaling
pathways important for infection. It has been experi-
mentally verified that HPV interaction with syndecan-1
via HSPG and binding of syndecan-1 to laminin 332 and
α6β4 integrin are in accordance with the notion that
HPV particles colocalize and interact with each of theseFigure 1 Heparan sulfate proteoglycans (HSPGs) are primary attachm
Syndecans are cell surface heparan sulfates. Laminin undergoes proteolytic
including integrin, syndecan and laminin receptor. CD151 is a member of t
different integrin α subunits, including α3, α6, and α7. EGFRs are internalize
infected cells. Matrix Metalloproteinases proteolytically cleave bound growt
complex can interact with different receptors to gain entry into the cervicaextracellular molecules [9]. Similarly, CD151-associated
integrins (α3β1 and α6β1/4) also regulate HPV16 infec-
tion [10]. HPV16 E6 activated mTORC1 by enhanced
signaling through miscellaneous receptors, including
EGFR, Insulin Receptor and insulin-like growth factor
receptors. It was shown that there was a prolonged in-
ternalized receptor and a gradual decline in cell surface
appearance of those receptors [11]. It has been reported
that HPV16 infection is lowest in α6 integrin null cells
and experimental methodologies have revealed that
Focal Adhesion Kinase (FAK) is the protein activated
upon integrin binding. HPV16 induces FAK-Tyr397
phosphorylation in cancer cells and it is intriguing to
note that targeted inhibition of α6 integrin function pre-
vents FAK-Tyr397 phosphorylation [12]. In line with the
same concept it is appropriate to mention that α2β1 in-
tegrin promotes tumor metastasis in HPV-induced squa-
mous cancer, probabilistically by promoting migratory
and invasive potential of cells [13]. However molecular
mechanisms are not studied in detail in cervical cancer
cells. Overview of HPV entry into cervical cells is shown
in the Figure 1.
Studies of cervical neoplasia suggest that HPV infec-
tion alone is not responsible for tumor developmentent molecules for entry of Human Papilloma Viruses into cells.
processing and can interact with different cell surface receptors
he tetraspanin group of transmembrane proteins and can interact with
d and there is a prolonged receptor mediated signaling in HPV
h factors and syndecans. These cleaved moieties bind to HPV and this
l cells.
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gets for HPV integration in cervical tumors. Convincing
substantiation of this relationship was first provided
when the sequence of the FRA3B region at 3p14.2 and
cellular sequences flanking an HPV16 integration in a
cervical tumor were indicated to be identical [14]. It has
also been documented that HPV16 integration in CFS
results in loss of tumor suppressor genes [15]. E7 on-
coprotein interacts primarily with the pATM and it is
appropriate to mention that ATM pathway is utilized by
HPVs to promote viral replication in differentiating cells
[16]. However there is a conflicting report that suggested
that ATM mediated signaling induced cell cycle arrest in
cervical cancer cells. Furthermore, cervical cancer cells
treated with isoliquiritigenin (ISL) displayed an activated
ATM that activated its downstream effectors. In addition
there was considerably enhanced ratio of pro-apoptotic
proteins Hsu et al, [17].
Sp1 DNA binding sites are present within HPV pro-
moters and play an active role in HPV gene expression.
Cells expressing HPV promoter luciferase reporter vec-
tor treated with nordihydroguaiaretic acid plant lignan
derivatives displayed remarkable repression of HPV en-
coded genes [18].
It is of particular significance that HPV 16 E5 oncogene
is a small, highly hydrophobic protein of 83 amino-acids
that localizes in endocellular membrane and undergoes
homo-oligomerization. This process of oligomerization
creates a hydrophilic pore that allows passage of small
molecules and ions through these channels [19]. It has
been experimentally verified that HPV16 E5 interferes
with degradative and recycling endocytic pathways of re-
ceptors. E5 protects degradation of receptors by inhibiting
the recruitment of Grb2-Cbl complexes responsible for re-
ceptor ubiquitination and degradation [20]. It is persuasive
to note that E5 regulates the expression of IFN-β via IRF-
1 and knockdown of IRF-1 expression in E5-expressing
cells abolishes IFN-β expression. Astonishingly, stimula-
tion of IRF-1 expression by HPV16 E5 occurs through E5
mediated activation of NF- κB that moves into the nucleus
to attach to consensus sequences on the IRF-1 gene pro-
moter [21].
Autophagy or "self-eating" is an important mechanism
and it has been shown that cellular decisions to autopha-
gy manipulation are modulated by HPV. Cells infected
with HPV16 displayed activated PI3K/Akt/mTOR path-
way that inhibited autophagy [22]. RECK is a membrane
bound protein and is a negative regulator of MMPs.
However it has been shown that E6 and E7 down-
regulate RECK and promote activity of MMP9. One pos-
sible mechanism could be miRNA mediated control of
RECK in cervical cancer cells [23]. Structural studies
provide reasonable evidence that conserved regions of
E7 are involved in interaction with different proteins.Transcriptional co-activator p300, which contains an in-
trinsic HAT activity, is essential for wide ranging bio-
logical functionalities is reported to be regulated by E7
via its CR1 and CR2 domains [24]. Similarly, E7 inter-
acts with pRb through its CR2 and CR3 domains [25].
TBX2 and TBX3 are members of the T-box family of
transcription factors and have been reported to repress
transcription from the LCR via interaction with HPV16
L2. CHIP analysis provided strong evidence of co-
localization of L2 and TBX2 in HPV16 positive CIN I-II
tissue sections [26].
ChIP assay confirm that HPV-18 E2 binds the hTERT
promoter region via Sp1in vivo and represses the expres-
sion of hTERT. However, HPV-16 E2 stimulates the
hTERT expression [27,28]. E5 is interconnected with
downregulation of antigen presentation by HLA class I
molecules, a protective mechanism that promotes HPVs
ability to evade immune clearance through cytotoxic-
T-lymphocyte (CTL)-mediated adaptive immunity. E5
restricts HLA-A and -B molecules in the golgi apparatus
thus repressing their cell surface appearance [29]. Simi-
lar mechanisms are opted by HPV to regulate CD1d, an
(MHC) class I-like glycoprotein. Cellular studies suggest
that E5-expressing epithelial cells retain CD1d in the ER
via interfering with the modification of HLA class I
heavy chains that characteristically takes place in the ER.
E5 has been documented to interact with calnexin in the
ER thus compromising calnexin-mediated CD1d folding
and impairing trafficking of CD1d to the surface of HPV-
infected cells [30].
HPV encoded E5 protein utilizes cAMP/PKA/CREB
pathway to stimulate the expression of Prostaglandin E2
(PGE2) receptor [31]. One of the best-characterized bio-
logical effects of 16E5 is ERK activation and it has add-
itionally shown that ERK specific phosphorylation sites
are present in E1-E4 protein. Predominantly, phospho-
rylation at threonine 57 enhances keratin binding and
provides protection against proteasomal degradation
[32]. It has previously been reported that HPV 16E1-E4
protein induces G2 arrest. It was further underscored
that arrest does not result from inhibition of the kinase
activity of the Cdk1/cyclin B1 complex rather due to re-
tention of active Cdk1/cyclin B1 complexes in the cyto-
plasm away from their nuclear substrates [33].
Spindle assembly checkpoint (SAC) is a 'wait-anaphase'
mechanism that has evolved in eukaryotic cells and spin-
dle checkpoint proteins (SCPs), sense the existence of
misaligned sister chromatids during mitosis and meiosis.
HPV16/18 E5 expressing cells have considerably reduced
expression of Bub1 and Mad2 [34]. NIH 3T3 cells
transfected with the HPV 16 full-length genome and mi-
metic miR-125b displayed drastic decrease in viral DNA
and protein synthesis however, co-transfection with anti-
miR-125b and HPV 16 markedly increased HPV DNA
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regulates spindle assembly checkpoint gene MAD1 [36].
Various splicing factors including ASF/SF2 are over-
expressed in high-grade cervical lesions and cervical
cancer. It was indicated that E2 caused a three- to four-
fold upregulation of SF2/ASF [37]. Using experimental
techniques it has been identified that 3'-splice site on
the HPV-16 genome, is used to produce primarily E4,
E6, and E7 mRNAs and is regulated by ASF/SF2. More
specifically, splice site is followed by 15 potential binding
sites for the splicing factor ASF/SF2 [38]. Rapidly in-
creasing research on post-transcriptional regulation of
HPV 16 indicates that hnRNPA1 and hnRNPA2 promote
HPV16 E6 exon exclusion, whereas Brm and Sam68 me-
diate exon inclusion [39]. It has also been suggested that
hnRNP A1 binding to the HPV-16 late 3′ splice site pre-
vents the interaction of the splice site with the U2AF35/
U2AF65 factors, thus inhibiting splicing [40].
Laboratory analysis of immortal human cell lines trans-
fected with E6 also suggests that E6 oncoproteins are cha-
racterized by the presence of a PDZ (PSD95/Dlg/ZO-1)
binding motif in their extreme carboxy termini. PDZ
domain-containing cellular substrates, including the cell
polarity regulators human Dlg (hDlg) (11) and human
Scribble (hScrib) have been identified to be known targets
of E6. Furthermore, other E6 PDZ domain-containing tar-
gets consist of the MAGI family of proteins, which act as
scaffolds in the regulation of tight-junction (TJ) assembly
[41]. Moreover there are additional targets which are
reported to be regulated by HPV encoded proteins. It is
now recognized that human cells express a unique family
of sense and antisense mitochondrial ncRNAs. Sense
transcript or SncmtRNA (SncmtRNA-1), is expressed in
normal proliferating cells and cancer cells. Antisense tran-
scripts (ASncmtRNA-1 and -2) are down-regulated which
highlights an important step during neoplastic transform-
ation and progression. Details of mechanism involved re-
veal that immortalization of HFK with HPV-16 or 18
results in repression of antisense transcript through E2
and stimulation of expression of sense transcript via E6
and E7 [42]. E6 and E7 have also been noted to reduce the
expression of the globular heads of the C1q receptor
(gC1qR), a mitochondrial surface protein [43]. HPV16 E6/
E7 are involved in degradation of p130. Recent studies
identified that p130 and the related p107 protein are com-
ponents of a transcriptionally repressive complex termed
DREAM (or LINC). In this complex, p130 or p107 are as-
sociated with E2F4 or E2F5 and bind to the promoters of
genes thus maintaining cell cycle arrest. Sequestration of
p130/p107 and E2F4/5 from this complex results is recon-
stitution of core DREAM proteins via formation of a sub-
stitute complex with the B-myb transcription factor that
regulates transcription of gene subsets essential for mi-
tosis. Targeted inhibition of HPV16 E6/E7 results in cell-cycle arrest and reformation of the p130–DREAM com-
plex [44].
Signaling cascades in HPV infected cervical cancer cells
A growing appreciation of misrepresented signaling path-
ways prompts the realization that spatio-temporal deregu-
lation is likely to contribute broadly to cervical cancer
development and may affect the sensitivity and resistance
of cancer to targeted therapies. Tremendous experimental
work has been done in improving our knowledge that cer-
vical cancer arises from abnormal decision making by can-
cer cells. These decisions related to cell death or survival
are made by molecular signaling networks that process in-
formation from outside and from within the HPV infected
cervical cancer cells and initiate responses that determine
the cell's survival. We dissect this segment of discussion
into subheadings that describe regulation of linear signal-
ing cascades in HPV infected cells.
TGF signaling
Several hints have emerged that indicate that cervical
cancer is associated with loss of TGF-β responsiveness
(gradual decline in TGF receptors) and because cervical
epithelial differentiation is altered by E7. For a better un-
derstanding of the underlying mechanisms, status of
TGF-β2 and TGF-βRII expression was examined in
transgenic mice expressing the oncogene E7 of HPV16
under control of the human Keratin-14 promoter (K14-
E7 transgenic mice). The results indicated that there was
an overexpression of TGF-β2 and decrease of TGF-βRII
expression in this particular model of cervical carcino-
genesis [45]. HPV mediates TGFα induced c-fos/c-jun
heterodimer formation to regulate expression of onco-
genes Figure 2 [46]. Surprisingly, there is a research
work that illustrates that E6 and E7 encoded by HPV-16
induce activation of TGF beta1 promoter [47]. It was
additionally indicated by a contemporary study that
inhibition of E7 expression lowered the expression level
of TGF-beta1 and induced apoptosis [48]. Detailed
structural insights identified that a 9-bp sequence,
GGGGCGGGG, representing the consensus Sp1-binding
site between -109 and -100 of the TGF-beta 1 promoter,
was the major target for E6-mediated transactivation
[49]. There is progressive loss of HPV-16 E2 which is
higher in CIN3 than in CIN1 or CIN2, and there is a
correlation between loss of HPV-16 E2 expression and
loss of TGF-beta1 at the lesion site [50]. TGF-beta1 sig-
naling cascade is involved in induction of chromosomal
instability in HPV positive cervical cancer cells and in-
hibition of TGF-beta1 signaling by an inhibitor of
TGFRI prevented telomere-mediated chromosomal in-
stability [51].
Overexpression of SMAD2/3 may be involved in the
genesis of cervical cancer Figure 2 [52]. However this
Figure 2 Shows that HPV infected cervical cancer cells have
overexpressed SMAD2/SMAD3 and increased heterodimerization
of c-fos and c-jun. E7 is involved in regulating the expression of
TGFβ1. E7 was also suggested to facilitate nuclear localization of
SMAD proteins.
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gested that weak cytoplasmic SMAD4 staining and the ab-
sence of Smad4 nuclear staining was associated with poor
survival in cervical cancer patients [53]. E7 facilitated the
nuclear translocation of Smad proteins (SMAD 2, SMAD3
and SMAD4) in a ligand-independent manner. More intri-
guingly, E7 interacted with MH1 Domain of SMAD3 to
repress TGF-β-mediated transcription Figure 2 [27,28]. It
is necessary to have a better knowledge of regulation of
SMAD subsets by HPV encoded proteins in cervical
cancer cells. How these SMAD proteins are degraded
or rescued in HPV infected cancer cells to regulate
cancer progression still is incompletely understood.
SMAD7 heterozygous, silent G to C variant in codon
391 was reported in HPV positive and negative cervical
cancer samples. However this report did not identify a
relationship between SMAD7 mutation and carcino-
genesis [54].
However there is a direct piece of evidence that indi-
cates that TGF-beta1 and IL-4 repress HPV-16 oncogene
transcription [55]. Enforced expression of nuclear fac-
tor I in TGF-beta-sensitive HPV16-immortalized human
keratinocytes (HKc/HPV16) inhibited TGF-beta medi-
ated repression of E6 and E7 [56]. Experiments on trans-
genic mice provided evidence that HPV-11 transformed
xenografts showed up-regulation of TGF beta 1 expres-
sion and down-regulation of the expression levels of bcl-2,
c-myc, c-Ha-ras, c-jun and NFkB [57,58]. It is noteworthy
that HPV-16 transformed cells show down-regulation of
bcl-2 and NFkB as well as NFkB function upon TGF beta
1 treatment [57,58].It still is confusing whether TGF signaling initially acts
as a barrier to HPV encoded proteins associated activ-
ities. Putting pieces of evidence together indicate contra-
dictory roles of TGF signaling. It appears that TGF
signaling is induced in HPV infected cervical cancer cells
however other research findings reveal that HPV en-
coded proteins degrade SMAD proteins to repress TGF
signaling. Cervical carcinogenesis was noted in HPV
infected cells both in absence and presence of TGF sig-
naling. In depth studies are required to provide a de-
tailed mechanism.
Wnt signaling
Interestingly, high-throughput technologies, including
the analyses of protein networks have considerably
enhanced our current understanding that binding of
WNTs to frizzled (FZD) and LRP5 or LRP6 co-receptors
transduces a signal across the plasma membrane that re-
sults in the activation of the Dishevelled (DVL) protein.
Activated DVL inhibited the destruction complex and
facilitated accumulation of CTNNB1 in the nucleus
where it acted as a co-activator for Wnt target genes.
Results obtained through immunohistochemistry re-
vealed that normal cervical epithelium showed staining
of β-catenin only on the membrane. However, cytoplas-
mic and nuclear staining was observed only on the basal
proliferating layer of the normal stratified squamous epi-
thelium. There is further elaboration of Wnt signaling
mediated biological implications and it is clear that acti-
vation and stabilization of the catenin is controlled by
HPV encoded proteins and various other oncogenes.
SV40 small t antigen (smt) was reported to stabilize
catenin by inhibiting PP2A [59]. Moreover it is also sug-
gested that HPV encoded proteins stabilize catenin by
suppressing SIAH-1. SIAH-1 is a target gene of p53
which is degraded by HPV encoded proteins and
targeted inhibition of HPV encoded proteins resulted in
restoration of SIAH. Genetic and biochemical data have
demonstrated that E6 and E7 facilitated beta-catenin
nuclear accumulation [60].
These finding indicated that there is an activated Wnt/
β-catenin signaling cascade in HPV-associated premalig-
nant lesions that plays an efficient role in accelerating
cervical carcinogenesis. Activation of the Wnt pathway
acted as secondary events that are necessary for malig-
nant transformation of HPV-infected epithelial cells [61].
It is also relevant to mention that negative regulators of
Wnt signaling are epigenetically repressed and a recent
report clarifies an association between DKK3 and SFRP2
promoter methylation in cervical cancer [62].
Notch Signaling
As discussed in the introductory section that E2 functions
as a repressor of the viral upstream regulatory region
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oncogenes, therefore loss of E2 is a prerequisite for in-
creased E6/E7 expression. To identify whether the inhib-
ition of E6/E7 expression by activated Notch1 occurs at
the level of URR promoter activity, HeLa cells were transi-
ently transfected with a plasmid for the URR promoter
and an expression vector for activated Notch1. It was
noted that URR promoter activity was significantly re-
duced by cotransfection of the activated Notch1 expres-
sion. Additionally it was observed that Notch-1 repressed
URR by inhibiting AP-1. Notch1 inhibited c-Fos protein
and simultaneously enhanced another Fos family member,
Fra-1. Fra-1 lacked a transcription activating domain and
acted as a suppressor rather than an inducer of AP-1-
dependent transcription [63].
The data gained through electrophoretic mobility shift
assays indicated that Notch overexpression was correlated
to altered AP-1 DNA binding activity and complex
composition. After inducing a moderate level of Notch ex-
pression, an increased DNA binding was demonstrated
byAP-1. However cells transfected with high expression
levels of Notch displayed a decrease in cFos signal and an
increase in Fra1 signal [64]. It is convincing to note that
explants of HaCaT cells co-expressing Jagged1and E6/E7
generated tumors greater than 90 mm3. However, co-
expression of Delta1 and E6/E7 generated lesions of less
than 10 mm3. It was noted that Jagged-1 and E6/E7 co-
expressing cancer cells used PI3K/Akt signaling axis to in-
duce EMT [65]. More detailed insights suggest that
Jagged-1 induced HES-1 that repressed Manic Fringe
(negative regulator of Jagged-1 mediated signaling). These
HES1 binding sites were found at nucleotide position
−250 upstream of the transcriptional start site of Manic
Fringe [66]. Notch-1 is also indicated to behave differ-
ently as HPV infected cells use Notch-1 during the pro-
gression from cervical intraepithelial lesions (CIN) to
invasive cervical carcinoma [67].
Inducing apoptosis in HPV positive cancer cells
Cellular and molecular studies have outstandingly clari-
fied existing concepts of role of HPV in cervical cancer.
It is now evident that HPV oncoproteins transform
noncancerous epithelial cells into cancerous carcinomas
by targeting key tumor suppressors and pro-apoptotic
proteins and additionally impair tumor suppressor and
apoptotic pathways. Therefore multi-targeted approach
based on targeting of HPV encoded proteins and mis-
represented pathways has shown promise in restoring
apoptotic pathway. We subdivide next coming section
into generalized approaches in inducing apoptosis in
HPV infected cervical cancer cells and TRAIL mediated
signaling in HPV infected cervical cancer cells. Treating
cervical cancer cells with Withaferin A resulted in
downregulation of HPV-E6 and E7 oncoproteins [68]. Arecent report adds a new dimension to role of HPV-
16E6 in cervical cancer cells. It is intriguing to note that
enforced expression of 16-E6 in cervical cancer cells
stimulated the expression of p53 and induced apoptosis
[69]. Interestingly, leaf extract of Bryophyllum pinnata
was effective in repressing HPV18 transcription. It also
suppressed oncogenic c-Fos and c-Jun expression [70].
n-Hexane and chloroform extracts of Anisomeles
malabarica induced death in HPV16-positive cervical
cancer cells [71].
TRAIL mediated apoptosis
Progressively there is a significant accumulation of re-
search reports which have categorized HPV encoded
proteins as oncogenes that suppress apoptosis. In the
upcoming section we dissect viral encoding genes which
have been experimentally investigated regarding their
roles in cervical cancer progression and underlying
mechanisms which induce resistance against TRAIL me-
diated apoptosis.
Cellular studies indicate that TRAIL binds to several
distinct receptors and it is a well established piece of in-
formation that DR4 and DR5 contain the intracellular
death domain (DD) essential for the induction of apop-
tosis following receptor ligation. Contrary to this, DcR1
nor DcR2 are unable to induce apoptosis due to a
complete or partial lack of the intracellular DD, respec-
tively. Using high-throughput technologies, we are able
to understand that binding of TRAIL to TRAIL-R1
or TRAIL-R2 induces trimerization of TRAIL-R1 or
TRAIL-R2, and FADD binds to the trimerized TRAIL-
R1 or TRAIL-R2 death domains. Then, FADD acts as an
adaptor molecule that is involved in signal dissemin-
ation by recruiting caspase 8, which initiates a proteo-
lytic cascade involving other caspases eventually leading
to cell death [72]. TRAIL mediated signaling is shown
in Figure 3.
It has lately been shown that pretreating HPV16 E7
expressing cervical cancer cells with HDAC inhibitors
considerably sensitized cells to TRAIL. c-FLIP suppres-
sion by HDAC inhibitors restores death receptor-
mediated apoptosis in HeLa cells. HDAC inhibitors tar-
get anti-apoptotic proteins and induce TRAIL mediated
apoptosis in resistant cancer cells by enhancing surface
expression of TRAIL receptors and re-distribution of
TRAIL receptors into lipid rafts (reviewed by [73]). It
has previously been shown that E7 oncoprotein binds to
multiple functional partners, particularly pRB and
HDAC1 and HDAC2 [74]. However, targeted inhibition
of HPV16- E7 abolished HDAC inhibitors mediated
sensitization to TRAIL [75]. There is a contradictory re-
port that indicates that E6/E7-siRNA induces senescence
rather than apoptosis in SiHa cells [76]. Increasing
Figure 3 Shows regulation of pro-apoptotic and anti-apoptotic
proteins by HPV encoded proteins and compounds.
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the underlying mechanisms which are opted by HPV for
the development of cervical cancer, implying that HPVs
have evolved immunoevasive mechanisms. It is now
known that HPV escapes immunosurveillance by re-
pressing the genes involved in IFN signaling (STAT1),
proapoptotic genes (TRAIL), and pathogen recognition
receptors (TLR3, RIG-I, and MDA5) [77]. Cells treated
with cAMP analog 8-CPT-cAMP (adenylyl cyclase acti-
vator), PDE inhibitors (isobutylmethylxanthine) or PKA
inhibitors displayed an upregulated expression of Smac/
DIABLO. This observation signifies the fact that cAMP/
PKA/CREB pathway is an important regulator of Smac/
DIABLO transcription [78]. Although it has been shown
that HPV encoded E5 protein utilizes cAMP/PKA/CREB
pathway to stimulate the expression of genes [31]. It
needs to be tested with reference to pro-apoptotic and
antiapoptotic gene subsets in cervical cancer cells.
E2F1has also been shown to directly bind and activate
the promoter of Smac/DIABLO, through the E2F1-
binding sites [79].
It is surprising to note that HPV-E2 gene disruption is
one of the key features of HPV-induced cervical malig-
nant transformation and is tumor suppressing gene
encoded by HPV. Laboratory investigations have re-
vealed that HPV16-E2 inhibits c-FLIP and renders cell
hypersensitive to apoptotic signal. It was confirmed by
overexpressing cFLIP in cancer cells that completely
hampered E2 mediated apoptotic response [80–83]. Co-immunoprecipitation and western blot analyses suggest
an interaction between HPV 16-E2 and cFLIP isoforms
thus inhibiting the recruitment of cFLIP to DISC. Char-
acteristically it has been suggested that targeting of p53
by HPV encoded proteins resulted in transcriptional re-
pression of Puma and abrogation of translocation of Bax
to mitochondrial membrane. Puma is a proapoptotic
protein that acts as an upstream activator of Bax, by in-
ducing a conformational change thus facilitating the
transmigration of Bax from the cytosol to the mitochon-
drial membrane [84]. Cervical cancer cells treated with
cyano analogue of boswellic acid displayed reduced viral
E6 mRNA expression and enhanced expression of Puma
through p53 pathway [85]. Antisense and peptide ap-
tamers targeting HPV E6/E7 have been shown to induce
target cell apoptosis through activation of pRb [86,87].
It has also been shown that p53 triggers the expression
of pro-apoptotic proteins (Noxa, Puma and Bax) and
repressed the expression of pro-proliferative factors
CyclinB1, cdc2, and Cdc25c [88]. Moreover there is
study that challenges classical concept of pRb in sup-
pressing cancer via negative regulation of E2F1. It high-
lights tumor suppressor role of E2F1. E2F1 up-regulates
the expression of the pro-apoptotic proteins PUMA,
Noxa and Bim. It needs detailed investigation in cervical
cancer cells to have a better understanding of the role of
E2F1 in cervical cancer progression. Keeping in view
tumor suppressor role of E2F1 it will be necessary to
identify relationship between pRb, E2F1 and regulation
of pro-apoptotic genes [89].
Targeted inhibition of HPV16-E6 resulted in restor-
ation of sensitivity to TRAIL [90]. There is sufficient ex-
perimental evidence that transfection of HPV16-E6 gene
into cells with wild-type p53, substantially decreased the
level of p53 protein, that resulted in suppression of DR4
induction by DNA-damaging agents [91]. Transiently
transfecting HPV16-E5 gene into immortalized human
keratinocyte cell line HaCaT severely repressed activa-
tion of caspase-3 upon TRAIL and FasL treatment [92].
Confluence of information suggests that HPV degrades
p53 that results in suppression of p53 mediated expres-
sion of death receptors. However there is a finding that
shows that IFN-beta increases TRAIL expression both
directly at the mRNA level and indirectly by enhancing
surface protein levels [93]. HPV16-E6 positive cervical
cancer cells displayed a rapid reduction in the protein
levels of both FADD and procaspase 8, which resulted in
suppression of the activation of caspases 8, 3 and 2 [94].
FZD8 was found to be highly expressed in HeLa cells
and in future it would be interesting to note if targeting
of FZD8 in cervical cancer cells could be helpful in over-
coming resistance against TRAIL [95]. Similar approach
has been tested in breast cancer cells and has been
shown to be effective [96].
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apoptosis
Researchers are targeting the anti-apoptotic machinery
and associated signaling cascades that impair TRAIL
mediated apoptosis. Wogonin, a flavonoid isolated from
the root of the medicinal herb Scutellaria baicalensis
Georgi was reported to be useful in sensitizing cervical
cancer cells to TRAIL [97]. It has lately been suggested
that bortezomib and nelfinavir considerably enhanced
the efficacy of an apoptosis-inducing TRAIL receptor
antibody [98]. Aspirin and TRAIL significantly repressed
ERK1/2 activation and down-regulated Mcl-1 [99]. Vari-
ous reports suggest that phosphorylated ERK1/2 induces
TRAIL resistant phenotype and aspirin has been shown
to inhibit pERK1/2. ERK pathway activation increases
the expression of prosurvival proteins, particularly
Mcl-1, by stimulating de novo gene expression. It is in-
triguing to note that expression of Mcl-1 in tumor cells
can be regulated at the transcriptional level or through
post translational modifications by ERK [100]. Arte-
sunate is an anti-malarial drug that is explored to be ef-
fective in sensitizing cervical cancer cells to TRAIL
mediated apoptosis by suppressing pro-survival proteins,
such as survivin, XIAP and Bcl-XL [101]. Noatbly strong
synergistic apoptosis-inducing effect of the combination
of rhTRAIL and MG132, particularly in CIN II/III le-
sions indicates that rhTRAIL combined with prote-
asome inhibitors open new horizons of therapeutic
strategies for CIN II/III [102]. Luteolin synergistically
acts with rh TRAIL to induce apoptosis in HeLa cells
[103]. HPV control of TRAIL mediated signaling is
shown in Figure 3.
Stimulating the expression of DRs
Phenylethyl isothiocyanate (PEITC) increased the ex-
pression of the DR4 and DR5 in cervical cancer cells
[104]. Likewise, synergistic treatment with taxol and
pristimerin induced cervical cancer apoptosis by enhan-
cing intracellular ROS, upregulation of DR5 and acti-
vation of Bax [105]. Cisplatin also enhanced DR5
expression in cervical cancer cells [106]. Irradiation cells
showed a p53-dependent rise in DR5 membrane expres-
sion [107]. It is surprising to note that proteasome in-
hibitor MG132 substantially stimulated DR4 and DR5
membrane expression in HeLa. However in SiHa only
DR5 membrane expression was upregulated from almost
unnoticeable to notable levels independent of p53 [108].
This finding adds a new layer of information that p53 is
not indispensible for expression of DR5.
DR5 promoter contains multiple Sp1 binding sites,
which may contribute to the increased DR5 expression
[109,110]. Sp1 binding sites are also present in promoter
region of TRAIL gene [111]. It has also been shown that
Sp1 is phosphorylated by ERK that enhanced DNAbinding affinity of SP1 [112]. DNMT-mediated hy-
permethylation of promoter regions cause transcrip-
tional repression and it has been shown that epigenetic
repression is induced by DNMT in the proximity of the
TRAIL promoter [113]. Moreover, H3K27me3 epigenetic
mark at the DR5 promoter represses its expression.
However it has been indicated that interference strat-
egies directed against Suz12 and Ezh2 promoted DR5
expression [114]. It is also important to mention that in
HPV16 E6 and E7 expressing cervical cancer cells have
considerably enhanced DNMT activity and there is a
transcriptional down-regulation of E-Cadherin in these
cells [115,116]. It has been shown that JNK is involved
in stimulating the expression of DR through CHOP and
SP1. Using different kinase inhibitors, including the p42/
44 MAPK inhibitor PD098059, the p38 MAPK inhibitor
SB203580, and the JNK1/2 inhibitor SP600125 it was
confirmed that DR5 expression was regulated by JNK.
Among the inhibitors tested, the JNK1/2 inhibitor
SP600125 effectively impaired DCA-induced DR5 ex-
pression, whereas the p42/44 and p38 MAPK inhibitors
failed to repress DR5 expression. Cardamonin isolated
from black cardamom induces the expression of DRs
using CHOP and SP1. The relationship was confirmed
by abrogation of CHOP and SP1 that resulted in inhi-
bition of mediated up-regulation of DRs [117]. MEK
kinase 1 (MEKK1) is a serine threonine kinase that is ac-
tivated following etoposide treatment and activates IKK.
IKK mediated inactivation of IKB results in sequestra-
tion of NF-kappaB from IKB. NFKB translocates into
the nucleus to stimulate the expression of DR4 [118].
DR4 is a p53 target gene and is transcriptionally con-
trolled by p53 through a functional intronic p53 binding
site (p53BS) [119]. It is also relevant to mention that
cells treated with EGF show a decrease in DR5 ex-
pression. Detailed analysis indicates that EGF treatment
facilitates co-existence of NFKB with HDAC at the bind-
ing site present in intronic region of DR5. However
etoposide treatment inhibits NFKB mediated recruit-
ment of HDAC to binding site [120]. Cervical cancer
cells treated with naringin displayed increased cell
surface appearance of DR and mitochondria-mediated
apoptosis in human cervical cancer (SiHa) cells
Ramesh et al, [121].
It is becoming successively more understandable that
nanoparticles (NPs) have become an important tool in
many industries including healthcare. Substantial fraction
of information has revealed that compared with free
antitumor drugs, drug-loaded long-circulating nanovectors
show prolonged circulation time in plasma, enhanced ac-
cumulation in tumor tissues, and better-quality thera-
peutic activity. Functionalizing nanovectors with targeting
moieties can promote specific receptor-mediated en-
docytosis, limiting non-specific uptake into the normal
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nanocarriers to improve the specificity of the delivery sys-
tem and it has been shown that a nanocomplex system
between the positively charged TRAIL and the nega-
tively charged chondroitin sulfate (CS) (CS/TRAIL) was
designed and applied in poly (lactide-co-glycolide) (PLGA)
microspheres (MSs). The results indicated that TC-loaded
PLGA MSs significantly inhibited tumour growth [122].
Furthermore, another recently published work indicated
that nanoparticle modified with polyethyleneimine was ap-
plied to be a vector of TRAIL for cervical cancer gene
therapy [123].
TRAIL resistance has been frequently observed in can-
cer cells and different approaches are being tested to over-
come the TRAIL resistant phenotype. There are different
subsets of anti-apoptotic proteins which are over-
expressed thus inducing resistance against TRAIL. Results
have shown that natural flavonoid chrysin inhibited
STAT3 phosphorylation thus repressing transcriptional
regulation of Mcl-1. Proof of the concept was provided by
treating cervical cancer cells with STAT3‑specific inhi-
bitor, cucurbitacin-I, which decreased Mcl-1 levels and
enhanced TRAIL-induced cell death [124]. Likewise 5,
7-Dihydroxyflavone is a dietary flavonoid has also been
reported to overcome resistance against TRAIL by effec-
tively targeting STAT3 phosphorylation. Additionally,
Bcl-2, Mcl-1, and IAPs were down-regulated and pro-
apoptotic protein Bax was found to be up-regulated [125].
Equol is an isoflavan produced by intestinal bacteria and
has been shown to enhance TRAIL-induced apoptosis of
HeLa cells through a death receptor-mediated caspase
pathway. Data suggested that Equol enhanced TRAIL-
induced apoptosis through activation of caspase-3, -8, -9,
and cleavage of BID [126].
It is essential to investigate role of HPV encoded pro-
teins in suppressing TRAIL mediated apoptosis. How
HPV encoded proteins mediate expression of TRAIL,
DR4/DR5 and DcRs is insufficiently studied. It is aston-
ishing to note that HPV16 E2 and E6 are RNA-binding
proteins and contain a protein-RNA interaction domain
in their C-terminal regions. In addition, E2 and E6 inter-
act with multiple cellular splicing factors like serine/
arginine (SR) proteins [127]. This relationship of HPV
encoded proteins with regulators of mRNA splicing
needs detailed investigation with reference to TRAIL,
DRs and subsets of tumor suppressors. Moreover, im-
pairment of TRAIL mediated apoptosis in HPV infected
cancer cells needs additional laboratory based experi-
mentations addressing modes of repression of TRAIL
and DR4/DR5 at transcriptional and post-transcriptional
level. Do HPV encoded proteins recruit silencing ma-
chinery at TRAIL and DR4/5 promoters or is there a
miRNA mediated regulation of TRAIL and DR4/DR5 or
is there an enhanced degradation of DRs are somequestions which demand extensive research. Although
some cell type specific studies have revealed that c-Cbl-me-
diated ubiquitination of TRAIL receptors has a main role in
the endosomal sorting leading to the degradative pathway.
However none of the studies indicated any relationship be-
tween HPV encoded proteins in directing degradation of
DRs in cervical cancer cells [128]. However it is clear that
HPV encoded proteins use ubiquitin ligases (cullin 1 ubi-
quitin ligase complex) to degrade tumor suppressors [129].
Membrane-associated RING-CH (MARCH) ubiquitin lig-
ase is also reported to ubiquitinate TRAIL-R1 and im-
pairing its cell surface expression [130].
miRNA and HPV
Integrative genomics and genetics approaches have
proven to be a functional tool in elucidating the complex
relationships often found in gene regulatory networks
and reconstitution of tumor-suppressive miRNA, or
sequence-specific knockdown of oncogenic miRNAs by
‘antagomirs,’ has produced favorable antitumor outcomes
in experimental models. We discuss existing knowledge
gaps that need to be bridged prior to the consideration
of miRNA-based experimental cancer gene therapy.
These include our incomplete understanding of rate-
limiting cellular components that impact the efficiency
of this posttranscriptional gene-silencing phenomenon
in HPV expressing cervical cancer cells. We partition
this section into regulation of miRNAs by p53 and
miRNA subsets which are documented to suppress
and promote cervical cancer. We partition this section
into regulation of miRNAs by p53 and miRNA subsets
which are documented to suppress and promote cer-
vical cancer.p53 mediated regulation of miRNA subsets in HPV
infected cervical cancer
It is now clear that HPV encoded proteins target p53 to
inhibit apoptosis of host cells. In the next section we dis-
cuss subsets of miRNA which are known targets of p53
and are inhibited by degrading p53. Detailed studies sug-
gested that cortisol induced HPV-E6 expression and
suppressed p53 and miR-145 in cervical cancer cells.
MiR-145 expression in cervical cancer cells was wild-
type p53-dependent, and cortisol down-regulated miR-
145 expression [131]. miR-23b and miR-34a were also
known targets of P53 however HPV encoded proteins
repressed the expression of miR-23b by degrading p53
[80–83,132]. Figure 4. miR-15a/miR-16/miR195/miR-497
family, miR-143/miR-145 and the miR-106-363 cluster
appeared to be misrepresented in HPV positive cervical
cancer cells [133]. HPV encoded proteins regulate expres-
sion of miRNAs in infected cells and Figure 4 illustrates
the mechanisms.
Figure 4 Shows E7 mediated inhibition of pRB that results in sequestration of E2F. E2F moves into the nucleus to stimulate the expression
of miR-15b. E7 also directly represses miR-203 expression. Additionally, p53 triggers expression of miR-145, miR-23b and miR-34a. Therefore E7
indirectly repress the expression of target miRNAs by degrading p53. miRNAs in slanting boxes are over-expressed in cervical cancer cells.
Rectangular Boxes indicate post-transcriptional processing of gene subsets bi miRNAs.
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of sleeping beauty tale of miRNA
HPV encoded proteins use methylation machinery to
suppress tumor suppressor miRNAs and there is a dir-
ect piece of evidence that reveals hypermethylation of
miR-124a and miR-203 in the precursor lesions [134].
There is also considerable evidence regarding increased
methylation levels of hsa-miR-124-1 and hsa-miR-124-
2 that strongly correlated with reduced hsa-miR-124
expression in cervical tissue specimens [135]. miR-218
was also found to be downregulated [136]. It appears
that tumor suppressor miRNA subsets are repressed
by installing co-repressor machinery at the promoter
regions.Tumor suppressor miRNAs
Phosphoinositide 3-kinase catalytic subunit delta (PIK3CD)
is a miR-125b target and cells reconstituted with miR-
125b represented inhibition of PI3K/Akt/mTOR pathway ,
while Bid was up-regulated in miR-125b-overexpressing
cells [137]. MiR-384-5p is also a known regulator of
PIK3CD [138]. MiR-7 has been shown to disrupt PI3K/
Akt/mTOR signaling axis [139]. However precise role of
miR-384-5p and miR-7 needs to be determined in HPV
expressing cervical cancer cells.
miR-17-5p and miR-143 act as tumor suppressors in
cancer cells by targeting TP53INP1 and Bcl-2 respectively
[140–142]. Fascinatingly, overexpression of miR-424 re-
pressed the expression of checkpoint kinase 1 (Chk1) and
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214 negatively regulates N-acetylgalactosaminyltransferase
7 (GALNT7) and distinctly inhibits cervical cancer cell
proliferation, migration, and invasion [145]. miR-372 and
miR-223 are down-regulated in cervical cancer and restor-
ation of these miRNAs inhibited cell migration and inva-
sion [146,147]. miR-375 is a tumor suppressor gene and is
downregulated in cervical cancer cells however it has been
reported that HPV16 E6/E7 does not directly regulate
miR-375 expression [80–83,148].
It is noteworthy that transiently transfecting pre-miR-
34c-3p, in HPV positive cervical cancer cells caused
S-phase arrest and apoptosis [149]. It is worth describing
that introduction of expression vectors for miR-203 into
HPV positive cells substantially limited HPV amplifica-
tion. It has also been noted that miR-203 expression is
regulated through MAPK/PKC pathway and interest-
ingly, this pathway is hampered in E7 expressing cells.
Pharmacological activation of PKC pathway is speculated
to trigger the expression of miR-203 via AP-1, AP-2, and
Sp-1 transcription factor families whose binding sites are
present in miR-203. Therefore E7 expressing cells
treated with PKC activators did not display an increase
in expression of miR-203 [150]. E5 expressing cervical
cancer cells showed upregulated miR-146a and repressed
miR-324-5p [151]. MiR-497 is a tumor suppressor and
targets IGF-1R however it is downregulated in cervical
cancer cells [152]. It has been shown that cervical cancer
cells treated with mTOR inhibitors displayed an increase
in expression of miR-143. It was noted that mTOR was
involved in repressing the expression of miR-143 [153].
Additional studies are required to dissect the precise
pathway downstream to mTOR that represses the ex-
pression. Tumor suppressor miRNA subsets are shown
in Figure 5.
Oncomirs
miR-10a, miR-205 and miR-133b are upregulated in cervical
cancer and promote migration and invasion [154–156].
CYR61 and CTGF are members of the cysteine rich 61/Figure 5 Oncogenic miRNAs which are over-expressed in
cervical cancer cells.connective tissue growth factor/nephroblastoma (CCN)
family of growth regulators and have tumor suppressing
properties. However targeting of CYR61 and CTGF by
miR-205 promotes cellular proliferation [155]. CHL1
gene – close homolog of L1, also known as CALL - cell
adhesion L1-like encodes a one-pass trans-membrane cell
adhesion molecule (CAM) capable of both homotypic and
heterotypic binding and has tumor suppressing properties.
It is negatively controlled by miR-10a [154]. miR-133b
enhances cell proliferation via negative regulation of
mammalian sterile 20-like kinase 2 (MST2), cell division
control protein 42 homolog (CDC42) and ras homolog
gene family member A (RHOA). Additionally, miR-133b
overexpressing cells have activated AKT1 and ERK1/2
[156]. Up-regulation of miR-19a and miR-19b promoted
cell growth and invasion. The Cullin family member of
RING E3 ubiquitin ligases (CUL5) is negatively regula-
ted. Cullin-RING E3 ubiquitin ligase are involved in
chaperone-mediated protein regulation and act as tumor
suppressors. [143,144]. Therefore it is notable that HPV
encoded proteins use various strategies to inhibit Cullin 5
mediated degradation of oncoproteins. miR-20a promoted
migration and invasion of cervical cancer cells [157]. miR-
886-5p is overexpressed in cervical cancer cells and impair
apoptosis by negatively regulating Bax [158]. E7 protein of
HPV binds to pRB, a negative regulator of E2F that results
in sequestration of E2F from pRB. Binding sites for E2F1
and E2F3 have been identified in the promoter of miR-15b
and targeted inhibition of HPV16-E7 resulted in down-
regulation of miR-15b in cancer cells [159] Figure 4. It has
lately been shown that HPV16-positive cancer cells have a
downregulated miR-218. Detailed analysis showed that
HPV16-E6 oncoprotein suppressed the expression of
miR-218 and rescued Laminin 5 β3 (LAMB3). LAMB3 is
negatively regulated by miR-218 and cells reconstituted
with LAMB3 displayed enhanced migratory potential
[160]. Likewise, methylation-mediated transcriptional re-
pression of hsa-miR-149, -203 and -375 is noted in cer-
vical cancer [161]. miR-182 is an oncomir and inhibition
of miR-182 in HeLa xenograft mouse model, resulted in
tumor growth regression. Moreover expression of miRNA
subsets in cervical cancer cell lines displayed two up-
regulated (miR-182 and -183) and nine down-regulated
(miR-211, 145, 223, 150, 142-5p, 328, 195, 199b, 142-3p)
miRNAs [162]. hsa-miR-15a-3p induces apoptosis in can-
cer cells via negative regulation of Bcl-xL [163]. Similarly,
cell reconstructed with miR-214 showed increased expres-
sion of Bax, caspase-9, caspase-8 and caspase-3. Moreover,
it has been persuasively revealed that miR-214 is regulated
by DNA methylation and histone deacetylation [164].
NDRG2 distinctively enhanced Bcl-2 expression and in-
creased the Bcl-2/Bax ratio, which decreased sensitivity of
Hela cells to drug-induced apoptosis. However cancer
cells expressing miR-15b and miR-16 demonstrated a
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knock down stimulates the expression of miR-15b and
miR-16 [141,142]. Moreover a cell-type specific study indi-
cates that NDRG2 is negatively regulated by miR-650
[165]. Oncogenic miRNA subsets are shown in Figure 6.
There is a complicated network by which miRNA sub-
sets are transcriptionally triggered by downstream effec-
tors of various signaling cascades and in turn miRNA
subsets regulate modulators of signaling cascades. How
HPV encoded proteins reconstitute signaling, transcrip-
tional and epigenetic machinery to regulate tumor sup-
pressor miRNAs and oncomirs still is a mystery.
Cervical cancer therapy
On a similar note, Arsenic trioxide induced cervical
cancer apoptosis by downregulating HPV-E6 and
upregulating p53 [166]. There is a progressive increase
in improving the RNA interference strategies. In line
with this approach, it has recently been explored that
chitosan is appropriate as a carrier for delivery of siRNA
into cancer and delivery of chitosan/HPV16 E7 siRNA
nanoparticles in vivo is an effective therapy for cervical
cancer [167]. E6/E7 specific siRNA-induced transcrip-
tional gene silencing has recently been effectivley tested
in cervical cancer cells [168]. Chloroform Extract of
Rasagenthi Mezhugu, induced DNA damage and apop-
tosis in cervical cancer cells [169]. More interestingly,
anti-DR5 monoclonal antibody, MD5-1 with a DNA vac-
cine encoding calreticulin (CRT) linked to human papil-
lomavirus type 16 (HPV-16) E7 antigen (CRT/E7(detox))
provided unique opportunities for the development of
therapeutic strategies. The study revealed biological
functionality and highlighted that administration of
CRT/E7(detox) in mice bearing the E7-expressing tumor,
generated the most potent therapeutic anti-tumor effects
as well as highest levels of E7-specific CD8+ T cells
[170]. There is a finding that has demonstrated a correl-
ation between the shrinkage of HPV16 E6 and E7+ tu-
mors versus DC and LC infiltration in a murine modelFigure 6 Tumor suppressor miRNAs which are under-expressed
in cervical cancer cells.of cervical cancer thus adding new evidence of the pre-
clinical efficacy of Dendritic cells (DCs) and Langerhans
cells (LCs) mediated killing. There is also sufficient evi-
dence that suggests that expression of TRAIL decoy re-
ceptors is reduced following introduction of E6 and E7
into host cells [171]. Using different in-vitro strategies,
E6 and E7 proteins are targeted to suppress carcino-
genesis. These targeted approaches included treatment
of cervical cancer cells with biflavonoid amentoflavone,
curcumin and Ruthenium oligonucleotides. Cervical
cancer cells treated with hesperetin (flavonoid from cit-
rus fruits) displayed an upregulated Fas death receptor
and its adaptor protein FADD. Additionally, there was
an increased expression of different caspases, p53 and
Bax Alshatwi et al, [172].
It was shown that targeted inhibition of E6 and E7
resulted in rescue of p53 Lee et al. [173], Maher et al.
[174], Reschner et al. [175]. Moreover, delivery of mono-
clonal antibodies against E6 in transformed cervical
keratinocytes has also been tested. There was an en-
hanced p53 activity after targeting of E6 Togtema et al.
[176]. It needs to be pursued with reference to miRNA
subsets which are influenced after treatment with anti-
bodies against E6. Future studies must converge on add-
itional natural compounds with minimal off target effects
and considerable efficacy.
GRIM-19 has been acclaimed as tumor suppressor as
cells reconstituted with GRIM-19 displayed ubiquitina-
tion and degradation of E6AP, and disrupted the E6/
E6AP complex. The abrogation of E6/E6AP complex
protected p53 from degradation and promoted cell
apoptosis [177]. It is impelling to note that phenomenal
strides have been made in identifying regulators of cer-
vical cancer. A better understanding of positive and
negative regulators will enable the scientists to effect-
ively target oncogenes that promote HPV expression. In
line with this approach, it has recently been identified
that interaction of mixed lineage leukemia 5 gene
(MLL5β) with the AP-1-binding site at the distal region
of the HPV18 long control region led to activation of
E6/E7 transcription. Targeted inhibition of MLL5β dras-
tically repressed both E6 and E7 expression [178].
In line with this approach, it has been proved that
HPV E2 is negative transcriptional modulator of HPV
E6 and E7 oncogenes, and also an apoptosis-inducing
agent. There is an increasing trend of transiently trans-
fecting tumor suppressor genes into cancer cells to en-
hance the efficacy of chemotherapy and radiations. A
recent report indicated that oncolytic adenovirus armed
with human papillomavirus E2 gene in combination with
radiation demonstrated considerably augmented antitu-
mor efficacy [80–83]. Similarly, pretreatment with dihy-
drotanshinone increased radiation induced apoptosis in
cervical cancer cells through down-regulated HPV E6
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pentoxifylline sensitized human cervical tumor cells to
cisplatin-induced apoptosis by inhibiting NF-kappa B
and anti-apoptotic proteins [180]. Transgenic mouse
model has been developed with malignant cervical le-
sions allowing the study of the cooperative effect be-
tween HPV16-E6/E7 expression and the lack of RXRα in
cervical cancer development [181]. This model could be
useful to investigate efficacy of chemopreventive and
chemotherapeutic strategies. It has been persuasively
documented that acetoxychavicol acetate (ACA) with
cisplatin (CDDP) worked with effective synergy in HPV-
positive human cervical carcinoma cells and induced cell
death [182]. HPV encoded proteins control host proteins
using an array of post-translational modifications, many of
which create binding sites for specific protein-interaction
domains thus reconstructing signaling cascades for regula-
tion of cell proliferation. We have discussed common
strategies used by HPV encoded proteins for modulation
of protein network to impair apoptosis in host cells.
Conclusion
Signaling networks in cells are composed of upstream
and downstream subnetworks. The upstream subnet-
work contains the intertwined network of signaling path-
ways, while the downstream regulatory part controls
expression of tumor promoting, tumor suppressing, pro-
apoptotic, anti-apoptotic and microRNA subsets in a
context dependent manner. HPV encoded proteins have
emerged as centrally positioned hubs in regulation of
signaling cascades in cervical cancer. Recent studies have
revealed an extraordinarily complex network of proteins
that is regulated by HPV encoded proteins. This highly
interconnected network contrasts our conventional view
of the cervical cancer as a linear sequence of events. It
has lately been shown that Hh signaling is not induced
directly by HPV-encoded proteins instead Hh-activating
mutations are selected in cells initially immortalized by
HPV [183]. Darinaparsin (ZIO-101, S-dimethylarsino-
glutathione) is an organic arsenical and has been noted
to effectively inhibit Shh-induced Gli1 expression in cer-
vical cancer cells [184]. It seems that we still lack a
broader landscape of linear and integrated signaling
pathways in HPV infected cervical cancer cells. SHH sig-
naling related information is insufficient and needs de-
tailed investigation. Coordinate regulation of an miRNA
network by a signaling pathway may lead to unpredict-
able effects on proteins when combinatorial effects are
considered, and further exploration of the rules for such
interactions are needed in HPV expressing cervical can-
cer cells. It is appropriate to mention that miRNA sub-
sets under-expressed in cervical cancer cells can be used
to regulate the proficiency of cancer-specific adenoviral
vector that expressed TRAIL based on miRNA responseelements (MREs) of miRNAs whose levels were reduced
in cervical cancer. Similar approaches have been tested
using in bladder cancer and glioma using adenoviral
vector expressing TRAIL and introducing MREs of
miRNA subsets down-regulated in respective cancer
cells [185,186].
Unquestionably, the growing interest in this class of
regulatory RNAs will lead to continued classification of
miRNA expression particularly in cervical cancer and
recognition of novel miRNA subsets that may act as on-
cogenes and tumour suppressors. Moreover, it is essen-
tial to develop a multi-level cross-talk network of the
Notch, Wnt, TGF-β and SHH pathways, identify mutual
and pathway-specific components/regulators and pre-
dominantly how HPV encoded proteins mastermind
cross-talk between these pathways and other pathways.
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